Clinical trial
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in…
NCT00325416 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00325416 |
|---|---|
| Title | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. |
| Official title | A Study of Intensive-Dose Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | GlaxoSmithKline Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug, Procedure |
| Interventions | melphalan, topotecan (TPT), Autologous Stem Cell Rescue |
| Enrollment | 177 |
| Start date | Nov 19, 2001 |
| Primary completion | Jul 15, 2013 |
| Completion | Jan 30, 2018 |
| First posted | May 12, 2006 |
| Last update posted | Mar 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: